H35.383
Toxic maculopathy, bilateral
Clinical Classification Guidelines
Medical Intelligence & Overview
Toxic maculopathy is an eye condition characterized by damage to the macula, the central part of the retina responsible for sharp, detailed vision. When this damage occurs in both eyes simultaneously, it is referred to as bilateral toxic maculopathy. This condition is typically linked to exposure to harmful substances or medications that affect the retinal tissues, leading to visual disturbances. Recognizing the signs and understanding the causes are essential for early intervention and preserving vision.
Causes & Symptoms
Clinical Causes: Prolonged or high-dose use of certain medications such as chloroquine, hydroxychloroquine, or other drugs known to have retinal toxicity. Exposure to environmental toxins or chemicals that can accumulate in the eye tissue. Use of certain drugs or chemicals that produce oxidative stress or damage to retinal cells. In some cases, overdose or accidental ingestion of toxic substances that impact eye health.
Key Symptoms: Blurred or distorted central vision. Dark or blank spots in the central visual field (scotomas). Difficulty recognizing faces or reading. Color vision disturbances, such as a decrease in color intensity or brightness. Gradual worsening of vision over time. Possible visual discomfort or sensitivity to light.
Diagnostic & Treatment
Diagnosis Path: Comprehensive eye examination including visual acuity testing and fundoscopy to observe retinal changes. Optical coherence tomography (OCT) to assess retinal structure and detect thinning or damage of the macula. Fundus photography to document retinal abnormalities. Electroretinography (ERG) may be used to evaluate retinal function. Review of medication history and exposure to potential toxins to identify possible causes.
Treatment Protocols: Immediate discontinuation of the offending medication or exposure to the toxic substance, under medical supervision. Regular monitoring of visual function and retinal health to track progression or improvement. Use of nutritional supplements or antioxidant therapy in some cases, although evidence varies. Supportive visual aids or rehabilitation services to assist with vision impairment. In advanced cases, experimental therapies or participation in clinical trials may be considered.
Clinical Advice & FAQs
Billing Guidance
Is H35.383 a billable ICD-10 code?
Yes, H35.383 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report H35.383?
Clinical documentation must specify the nature of Toxic maculopathy, bilateral and any associated comorbidities for accurate reporting.
Cite this Clinical Reference